Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-25Current immunotherapeutic approaches in pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2011-05-06 / Cancer Immunol. Immunother. 2011 Aug;60(8):1097-107Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
/in Hyperthermia, International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2010-08-01 / Surgery 2010 Aug;148(2):325-34Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2009-06-01 / Int. J. Oncol. 2009 Jun;34(6):1701-15Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2009-05-01 / Int J Hyperthermia 2009 May;25(3):210-9A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2009-04-01 / Pancreas 2009 Apr;38(3):e69-74Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
/in International Publications, Pancreatic Cancer /von 2009-03-01 / Expert Opin Biol Ther 2009 Mar;9(3):331-9Biological approaches to therapy of pancreatic cancer
/in International Publications, Pancreatic Cancer /von 2008-08-25 / Pancreatology 2008;8(4-5):431-61
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de